<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576783</url>
  </required_header>
  <id_info>
    <org_study_id>183210</org_study_id>
    <nct_id>NCT01576783</nct_id>
  </id_info>
  <brief_title>Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes</brief_title>
  <official_title>Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarah Keim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allen Foundation Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>March of Dimes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cures Within Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Resources and Services Administration (HRSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether supplementation with certain polyunsaturated
      fatty acids can help the cognitive development of children born preterm.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment and Trial Completion</measure>
    <time_frame>Pre-baseline to 180 days post-randomization</time_frame>
    <description>Primary Outcome for 1st stage of project funded by Allen Foundation, Inc: The number of children who enroll in the trial and the proportion who return for study visits 2 and 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>Baseline to 180 days post-randomization</time_frame>
    <description>Primary Outcome for 1st stage of project funded by Allen Foundation, Inc: The proportion of children who adhere to the assigned supplement or placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatty Acid</measure>
    <time_frame>Baseline to 180 days post-randomization</time_frame>
    <description>Primary Outcome for 1st stage of project funded by Allen Foundation, Inc: Change in plasma and RBC fatty acid concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development</measure>
    <time_frame>Baseline to 180 days post-randomization</time_frame>
    <description>Secondary Outcome for 1st stage of project funded by Allen Foundation, Inc; Primary Outcome for 2nd stage of project funded by March of Dimes and HRSA: Changes in Bayley Scales of Infant and Toddler Development - 3rd edition scores from baseline to study visit 3.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Behavior</measure>
    <time_frame>Baseline to 180 days post-randomization</time_frame>
    <description>Differences in temperament (effortful control, activity level), social-emotional behavior, and sleep.</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Composition</measure>
    <time_frame>Baseline to 180 days post-randomization</time_frame>
    <description>Changes in body composition from baseline to 6 months post-randomization (weight, recumbent length, head circumference, mid-upper arm circumference, triceps and subscapular skinfolds).</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term efficacy in improving cognition</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) cognitive outcome. This will be evaluated based on scores from the cognitive section of the Developmental Profile - 3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term efficacy in improving executive functions</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P).</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term efficacy in improving executive functions</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the ADHD DSM oriented subscale of the Child Behavior Checklist 1.5-5 (CBCL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Pervasive Developmental Problems</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Pervasive Developmental Problems DSM oriented scale on the Child Behavior Checklist 1.5-5 (CBCL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Language</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Communicative Development Inventory (CDI).</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Sleep</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Brief Infant Sleep Questionnaire (BISQ).</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Sleep</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Children's Sleep Habits Questionnaire (CSHQ).</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Growth</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using growth data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Developmental Delay</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using reports/diagnoses of developmental delay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other long-term outcomes: Behavior</measure>
    <time_frame>Long-term effect (6 months +) after intervention completion</time_frame>
    <description>Long-term (26-32 months of age) outcomes. This will be evaluated using reports/diagnoses of behavioral difficulties.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">377</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Child Development</condition>
  <arm_group>
    <arm_group_label>DHA arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA+AA supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn oil supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA+AA</intervention_name>
    <description>200 mg DHA + 200 mg AA per day for 6 months</description>
    <arm_group_label>DHA arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400 mg corn oil per day for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 10-16 months (age corrected for prematurity) at baseline

          2. Discontinued regular breastfeeding and formula feeding at the time of randomization

          3. Gestational age &lt; 35 completed weeks at birth

          4. English is primary language in home

          5. Informed consent obtained and signed

          6. Child admitted to any NCH managed NICU or children who have ever had a Neonatology
             Clinic follow up visit scheduled, regardless of attendance

        Exclusion Criteria:

          1. Feeding problems

          2. Major malformation, metabolic, or digestive disorder that would preclude participation
             and/or optimal absorption of the supplement.

          3. Weight &lt; 5th or &gt; 95th percentile for age, per WHO growth charts

          4. Consume DHA supplement drops, chews, or powders or Pediasure, or fatty fish more than
             2x per week

          5. Plans to move out of the area within the next 6 months

          6. Known corn allergy

          7. Known soy allergy

          8. Known fish allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Months</minimum_age>
    <maximum_age>16 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Keim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sarah Keim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

